Study of INCB053914 in Subjects With Advanced Malignancies

NCT02587598 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: INCB053914
DRUG: I-DAC (Intermediate dose cytarabine)
DRUG: Azacitidine
DRUG: Ruxolitinib

Sponsor

Incyte Corporation